Archives
-
HyperScribe™ mRNA Kit: Evidence in CAR-T
2026-10-07
Explore how mRNA design and analytical interpretation intersect in in vivo CD19 CAR-T research for lupus. This evidence-focused review places the HyperScribe™ mRNA synthesis kit in context without overstating what a preclinical mouse study or an individual reagent system can establish.
-
CBD, CB1 Signaling, and Orofacial Pain
2026-10-07
The 2026 Brain Research Bulletin study examines cannabidiol (CBD) as a multimodal intervention for inflammatory orofacial pain and pain-related affective deficits in mice. Its central contribution is the separation of peripheral CB2-associated anti-inflammatory effects from central CB1-linked modulation of pain processing, while also connecting chronic pain relief with serotonergic activity in the central amygdala.
-
Fosinopril Sodium in Hypertension Research
2026-10-06
A source-grounded overview of fosinopril sodium as a phosphinic acid ACE inhibitor, covering prodrug activation, pharmacokinetics, blood pressure findings, renal and cardiac research contexts, evidence strength, and important limitations.
-
Captopril, ACE Inhibition, and Ileal Peristalsis
2026-10-06
Captopril is an ACE inhibitor with established relevance to hypertension research, while a 2006 guinea pig ileum study identified bradykinin B2 receptors as inhibitory regulators of the peristaltic reflex. The findings create a useful conceptual bridge between ACE–kinin biology and gastrointestinal pharmacology, but they do not directly demonstrate an effect of Captopril, nor do they establish human or anticancer applications.
-
Ko 143: A Causal Framework for BCRP Research
2026-10-05
Ko 143 is a selective BCRP inhibitor for separating transporter-driven exposure changes from broader formulation and metabolism effects. This article connects Ko 143 with a 2026 quercetin study to develop a causality-focused framework for multidrug resistance and pharmacokinetic research.
-
Heart–Brain Axis Dysregulation in PTSD Mice
2026-10-05
A 2026 European Journal of Pharmacology study connects sympathetic cardiac overactivation with insular cortex hyperactivity and PTSD-like behavior through a vagal pathway in mice. Its combination of isoproterenol modeling, vagotomy, electrophysiology, immunofluorescence, and propranolol intervention strengthens a mechanistic heart–brain interpretation while remaining limited to preclinical evidence.
-
SU6656 in hiPSC Platelet Research: Evidence and Limits
2026-10-04
A source-grounded overview of SU6656, Src signaling, and the 2026 study of hiPSC-derived platelets, with emphasis on what the evidence supports, what remains unproven, and why the study should not be read as clinical or radiotherapy guidance.
-
Angiotensin III: RAAS Biology and New Evidence
2026-10-03
Angiotensin III is a downstream renin–angiotensin system peptide with established interest in aldosterone regulation, vascular signaling, and neuroendocrine biology. A 2025 molecular study also reported that angiotensin III enhanced SARS-CoV-2 spike-protein binding to host receptors, but the finding remains mechanistic and in vitro rather than evidence of clinical causation.
-
Mildronate Lipidoids for Lower-Inflammation mRNA Vaccines
2026-10-02
The 2024 ACS Nano study developed mLNP-69, a lipid nanoparticle using a low dose of mildronate-derived cationic lipid to preserve mRNA delivery while reducing local inflammation. In prophylactic and therapeutic B16OVA melanoma models, the formulation supported tumor prevention or delayed progression, providing a preclinical framework for separating delivery efficiency from lipid-associated inflammatory effects.
-
Ko 143: A Causal Tool for BCRP Exposure Studies
2026-10-01
Ko 143 is a selective BCRP inhibitor for separating transporter-mediated drug efflux from metabolism, solubility, and formulation effects. This article develops an assay-to-pharmacokinetic framework inspired by recent PEG 400–quercetin research and applies it to multidrug resistance and chemotherapy studies.
-
Epinephrine Bitartrate in Arrhythmia Research
2026-10-01
Explore how Epinephrine Bitartrate can model catecholamine-driven physiology in arrhythmia and adrenergic signaling studies. This article contrasts broad receptor activation with atrium-focused pharmacology and translates clinical trial design into practical assay decisions.
-
Ko 143: A Causal Framework for BCRP Studies
2026-09-30
Ko 143 is a selective BCRP inhibitor for testing whether ABCG2-driven efflux causes altered drug response or exposure. This article develops a causal, transporter-aware framework that connects cancer resistance assays with pharmacokinetic and formulation studies.
-
Vernakalant for Rapid Atrial Fibrillation Conversion
2026-09-30
This phase 3 randomized trial showed that intravenous vernakalant converted short-duration atrial fibrillation to sinus rhythm substantially faster and more often than placebo, with a median conversion time of 11 minutes. Its atrium-focused ion-channel pharmacology provides a useful model for rapid drug conversion, while the observed hypotension and conduction-related events underscore the need for monitored administration.
-
Evacetrapib (LY2484595) in Ferroptosis Assays
2026-09-29
Evacetrapib (LY2484595) offers a useful pharmacological lens for separating CETP-linked lipid biology from hydrogen sulfide-driven ferroptosis. This article translates recent NSCLC findings into a rigorous assay strategy while defining what can—and cannot—be inferred from combining these systems.
-
Epinephrine Bitartrate in Adrenergic Assays
2026-09-29
Epinephrine Bitartrate supports both rapid functional activation studies and receptor-affinity measurements across cardiovascular, neurobiology, and sympathetic nervous system models. This guide pairs practical cell-assay workflows with the part-coated capillary electrochromatography strategy reported for β2-adrenergic receptor binding.